Tokyo Tape
Sign in
← Taiko Pharmaceutical

Annual report

4574.TEDINET S100QI1S
Period2022-01-01 → 2022-12-31
Filed2023-03-30
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 152
MetricValuePeriodScopeSource row
Revenue¥5.0bn2022-01-01 → 2022-12-31Cons.Net sales
Revenue¥11.3bn2021-01-01 → 2021-12-31Cons.Net sales
Revenue¥17.6bn2020-01-01 → 2020-12-31dCons.Net sales (5-year summary)
Revenue¥15.0bn2019-01-01 → 2019-12-31dCons.Net sales (5-year summary)
Revenue¥10.4bn2018-01-01 → 2018-12-31dCons.Net sales (5-year summary)
Operating income−¥3.1bn2022-01-01 → 2022-12-31Cons.Operating income
Operating income−¥4.9bn2021-01-01 → 2021-12-31Cons.Operating income
Ordinary income−¥3.4bn2022-01-01 → 2022-12-31Cons.Ordinary income
Ordinary income−¥6.1bn2021-01-01 → 2021-12-31Cons.Ordinary income
Ordinary income¥5.5bn2020-01-01 → 2020-12-31dCons.Ordinary income loss (5-year summary)
Ordinary income¥3.6bn2019-01-01 → 2019-12-31dCons.Ordinary income loss (5-year summary)
Ordinary income¥1.9bn2018-01-01 → 2018-12-31dCons.Ordinary income loss (5-year summary)
Profit before tax−¥4.9bn2022-01-01 → 2022-12-31Cons.Income before income taxes
Profit before tax−¥8.9bn2021-01-01 → 2021-12-31Cons.Income before income taxes
Net income (owners)−¥4.9bn2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)−¥9.6bn2021-01-01 → 2021-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥3.9bn2020-01-01 → 2020-12-31dCons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥2.5bn2019-01-01 → 2019-12-31dCons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.4bn2018-01-01 → 2018-12-31dCons.Profit loss attributable to owners of parent (5-year summary)
Net income−¥4.9bn2022-01-01 → 2022-12-31Cons.Profit loss
Net income−¥9.6bn2021-01-01 → 2021-12-31Cons.Profit loss
Total assets¥15.0bnat 2022-12-31Cons.Assets
Total assets¥22.5bnat 2021-12-31Cons.Assets
Total assets¥31.8bnat 2020-12-31dCons.Total assets (5-year summary)
Total assets¥25.5bnat 2019-12-31dCons.Total assets (5-year summary)
Total assets¥21.6bnat 2018-12-31dCons.Total assets (5-year summary)
Total liabilities¥7.0bnat 2022-12-31Cons.Liabilities
Total liabilities¥9.7bnat 2021-12-31Cons.Liabilities
Net assets / equity¥8.0bnat 2022-12-31Cons.Net assets
Net assets / equity¥12.8bnat 2021-12-31Cons.Net assets
Net assets / equity¥22.8bnat 2020-12-31dCons.Net assets
Net assets / equity¥19.4bnat 2019-12-31dCons.Net assets (5-year summary)
Net assets / equity¥17.5bnat 2018-12-31dCons.Net assets (5-year summary)
Cash and deposits¥3.1bnat 2022-12-31Cons.Cash and deposits
Cash and deposits¥5.8bnat 2021-12-31Cons.Cash and deposits
Cash & equivalents¥2.8bnat 2022-12-31Cons.Cash and cash equivalents
Cash & equivalents¥5.5bnat 2021-12-31Cons.Cash and cash equivalents
Cash & equivalents¥4.7bnat 2020-12-31dCons.Cash and cash equivalents
Cash & equivalents¥9.6bnat 2019-12-31dCons.Cash and cash equivalents (5-year summary)
Cash & equivalents¥7.2bnat 2018-12-31dCons.Cash and cash equivalents (5-year summary)
Operating cash flow−¥2.0bn2022-01-01 → 2022-12-31Cons.Net cash provided by used in operating activities
Operating cash flow−¥1.6bn2021-01-01 → 2021-12-31Cons.Net cash provided by used in operating activities
Operating cash flow−¥1.5bn2020-01-01 → 2020-12-31dCons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥3.5bn2019-01-01 → 2019-12-31dCons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥1.7bn2018-01-01 → 2018-12-31dCons.Net cash provided by used in operating activities (5-year summary)
Investing cash flow¥190m2022-01-01 → 2022-12-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥1.6bn2021-01-01 → 2021-12-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥2.8bn2020-01-01 → 2020-12-31dCons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥448m2019-01-01 → 2019-12-31dCons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥746m2018-01-01 → 2018-12-31dCons.Net cash provided by used in investing activities (5-year summary)
Financing cash flow−¥997m2022-01-01 → 2022-12-31Cons.Net cash provided by used in financing activities
Financing cash flow¥4.0bn2021-01-01 → 2021-12-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥649m2020-01-01 → 2020-12-31dCons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥581m2019-01-01 → 2019-12-31dCons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥338m2018-01-01 → 2018-12-31dCons.Net cash provided by used in financing activities (5-year summary)
EPS (basic)¥-112.262022-01-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-220.522021-01-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥89.182020-01-01 → 2020-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥57.572019-01-01 → 2019-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥332018-01-01 → 2018-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥88.822020-01-01 → 2020-12-31dCons.Diluted earnings per share (5-year summary)
EPS (diluted)¥57.342019-01-01 → 2019-12-31dCons.Diluted earnings per share (5-year summary)
EPS (diluted)¥32.962018-01-01 → 2018-12-31dCons.Diluted earnings per share (5-year summary)
Net assets per share¥184.6at 2022-12-31Cons.Net assets per share (5-year summary)
Net assets per share¥293.88at 2021-12-31Cons.Net assets per share (5-year summary)
Net assets per share¥525.83at 2020-12-31dCons.Net assets per share (5-year summary)
Net assets per share¥450.94at 2019-12-31dCons.Net assets per share (5-year summary)
Net assets per share¥405.41at 2018-12-31dCons.Net assets per share (5-year summary)
Equity ratio53.5%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio56.8%at 2021-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio71.7%at 2020-12-31dCons.Equity to asset ratio (5-year summary)
Equity ratio76.0%at 2019-12-31dCons.Equity to asset ratio (5-year summary)
Equity ratio80.8%at 2018-12-31dCons.Equity to asset ratio (5-year summary)
ROE-47.0%2022-01-01 → 2022-12-31Cons.Rate of return on equity (5-year summary)
ROE-53.9%2021-01-01 → 2021-12-31Cons.Rate of return on equity (5-year summary)
ROE18.3%2020-01-01 → 2020-12-31dCons.Rate of return on equity (5-year summary)
ROE13.3%2019-01-01 → 2019-12-31dCons.Rate of return on equity (5-year summary)
ROE8.4%2018-01-01 → 2018-12-31dCons.Rate of return on equity (5-year summary)
Employees210at 2022-12-31Cons.Number of employees
Employees264at 2021-12-31Cons.Number of employees
Employees274at 2020-12-31dCons.Number of employees
Employees233at 2019-12-31dCons.Number of employees
Employees229at 2018-12-31dCons.Number of employees
Revenue¥4.6bn2022-01-01 → 2022-12-31StandaloneNet sales
Revenue¥10.6bn2021-01-01 → 2021-12-31StandaloneNet sales
Revenue¥17.1bn2020-01-01 → 2020-12-31dStandaloneNet sales (5-year summary)
Revenue¥14.5bn2019-01-01 → 2019-12-31dStandaloneNet sales (5-year summary)
Revenue¥9.9bn2018-01-01 → 2018-12-31dStandaloneNet sales (5-year summary)
Operating income−¥3.0bn2022-01-01 → 2022-12-31StandaloneOperating income
Operating income−¥5.0bn2021-01-01 → 2021-12-31StandaloneOperating income
Ordinary income−¥3.3bn2022-01-01 → 2022-12-31StandaloneOrdinary income
Ordinary income−¥5.9bn2021-01-01 → 2021-12-31StandaloneOrdinary income
Ordinary income¥5.5bn2020-01-01 → 2020-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥3.5bn2019-01-01 → 2019-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥1.8bn2018-01-01 → 2018-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥4.9bn2022-01-01 → 2022-12-31StandaloneIncome before income taxes
Profit before tax−¥8.6bn2021-01-01 → 2021-12-31StandaloneIncome before income taxes
Net income−¥5.0bn2022-01-01 → 2022-12-31StandaloneProfit loss
Net income−¥9.3bn2021-01-01 → 2021-12-31StandaloneProfit loss
Net income¥3.9bn2020-01-01 → 2020-12-31dStandaloneNet income loss (5-year summary)
Net income¥2.4bn2019-01-01 → 2019-12-31dStandaloneNet income loss (5-year summary)
Net income¥1.3bn2018-01-01 → 2018-12-31dStandaloneNet income loss (5-year summary)
Total assets¥14.3bnat 2022-12-31StandaloneAssets
Total assets¥21.9bnat 2021-12-31StandaloneAssets
Total assets¥31.0bnat 2020-12-31dStandaloneTotal assets (5-year summary)
Total assets¥24.6bnat 2019-12-31dStandaloneTotal assets (5-year summary)
Total assets¥20.9bnat 2018-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥6.8bnat 2022-12-31StandaloneLiabilities
Total liabilities¥9.5bnat 2021-12-31StandaloneLiabilities
Net assets / equity¥7.5bnat 2022-12-31StandaloneNet assets
Net assets / equity¥12.4bnat 2021-12-31StandaloneNet assets
Net assets / equity¥22.2bnat 2020-12-31dStandaloneNet assets
Net assets / equity¥18.8bnat 2019-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥16.9bnat 2018-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥1.9bnat 2022-12-31StandaloneCash and deposits
Cash and deposits¥4.8bnat 2021-12-31StandaloneCash and deposits
EPS (basic)¥-113.642022-01-01 → 2022-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-213.032021-01-01 → 2021-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥89.572020-01-01 → 2020-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥55.312019-01-01 → 2019-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥31.092018-01-01 → 2018-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (diluted)¥89.212020-01-01 → 2020-12-31dStandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥55.092019-01-01 → 2019-12-31dStandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥31.052018-01-01 → 2018-12-31dStandaloneDiluted earnings per share (5-year summary)
Dividend per share¥252020-01-01 → 2020-12-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥502019-01-01 → 2019-12-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥352018-01-01 → 2018-12-31dStandaloneDividend paid per share (5-year summary)
Net assets per share¥171.91at 2022-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥284.83at 2021-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥512.14at 2020-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥436.46at 2019-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥392.92at 2018-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio52.4%at 2022-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio56.6%at 2021-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio71.6%at 2020-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio76.1%at 2019-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio80.9%at 2018-12-31dStandaloneEquity to asset ratio (5-year summary)
ROE-49.8%2022-01-01 → 2022-12-31StandaloneRate of return on equity (5-year summary)
ROE-53.6%2021-01-01 → 2021-12-31StandaloneRate of return on equity (5-year summary)
ROE18.9%2020-01-01 → 2020-12-31dStandaloneRate of return on equity (5-year summary)
ROE13.2%2019-01-01 → 2019-12-31dStandaloneRate of return on equity (5-year summary)
ROE8.1%2018-01-01 → 2018-12-31dStandaloneRate of return on equity (5-year summary)
Shares issued44,136,900at 2022-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued44,136,900at 2021-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued44,001,900at 2020-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued14,567,300at 2019-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued14,344,100at 2018-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees175at 2022-12-31StandaloneNumber of employees
Employees226at 2021-12-31StandaloneNumber of employees
Employees237at 2020-12-31dStandaloneNumber of employees
Employees211at 2019-12-31dStandaloneNumber of employees
Employees207at 2018-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 58
SegmentItemPeriodValue
Otherother segmentsrevenue2022-01-01 → 2022-12-31¥7m
Otherother segmentsrevenue external2022-01-01 → 2022-12-31¥7m
Otherother segmentssegment assetsat 2022-12-31¥10m
Otherother segmentssegment profit2022-01-01 → 2022-12-31−¥44m
Reconciling Itemsreconcilingcapex2022-01-01 → 2022-12-31¥20m
Reconciling Itemsreconcilingdepreciation2022-01-01 → 2022-12-31¥128m
Reconciling Itemsreconcilingsegment assetsat 2022-12-31¥5.4bn
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-12-31−¥1.2bn
Infection Control Businessreportable segmentcapex2022-01-01 → 2022-12-31¥5m
Infection Control Businessreportable segmentdepreciation2022-01-01 → 2022-12-31¥60m
Infection Control Businessreportable segmentemployeesat 2022-12-3176 pure
Infection Control Businessreportable segmentrevenue2022-01-01 → 2022-12-31¥1.4bn
Infection Control Businessreportable segmentrevenue external2022-01-01 → 2022-12-31¥1.4bn
Infection Control Businessreportable segmentsegment assetsat 2022-12-31¥1.8bn
Infection Control Businessreportable segmentsegment profit2022-01-01 → 2022-12-31−¥2.2bn
Pharmaceuticals Businessreportable segmentcapex2022-01-01 → 2022-12-31¥17m
Pharmaceuticals Businessreportable segmentdepreciation2022-01-01 → 2022-12-31¥549m
Pharmaceuticals Businessreportable segmentemployeesat 2022-12-31109 pure
Pharmaceuticals Businessreportable segmentrevenue2022-01-01 → 2022-12-31¥3.6bn
Pharmaceuticals Businessreportable segmentrevenue external2022-01-01 → 2022-12-31¥3.6bn
Pharmaceuticals Businessreportable segmentsegment assetsat 2022-12-31¥7.8bn
Pharmaceuticals Businessreportable segmentsegment profit2022-01-01 → 2022-12-31¥297m
—segment totalemployeesat 2022-12-31185 pure
Total Of Reportable Segments And Otherssegment totalcapex2022-01-01 → 2022-12-31¥22m
Total Of Reportable Segments And Otherssegment totaldepreciation2022-01-01 → 2022-12-31¥609m
Total Of Reportable Segments And Otherssegment totalrevenue2022-01-01 → 2022-12-31¥5.0bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-01-01 → 2022-12-31¥5.0bn
Total Of Reportable Segments And Otherssegment totalsegment assetsat 2022-12-31¥9.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-01-01 → 2022-12-31−¥1.9bn
Otherother segmentsrevenue2021-01-01 → 2021-12-31¥6m
Otherother segmentsrevenue external2021-01-01 → 2021-12-31¥6m
Otherother segmentssegment assetsat 2021-12-31¥12m
Otherother segmentssegment profit2021-01-01 → 2021-12-31−¥68m
Reconciling Itemsreconcilingcapex2021-01-01 → 2021-12-31¥117m
Reconciling Itemsreconcilingdepreciation2021-01-01 → 2021-12-31¥109m
Reconciling Itemsreconcilingsegment assetsat 2021-12-31¥8.4bn
Reconciling Itemsreconcilingsegment profit2021-01-01 → 2021-12-31−¥1.4bn
Infection Control Businessreportable segmentcapex2021-01-01 → 2021-12-31¥309m
Infection Control Businessreportable segmentdepreciation2021-01-01 → 2021-12-31¥472m
Infection Control Businessreportable segmentrevenue2021-01-01 → 2021-12-31¥6.9bn
Infection Control Businessreportable segmentrevenue external2021-01-01 → 2021-12-31¥6.9bn
Infection Control Businessreportable segmentsegment assetsat 2021-12-31¥4.1bn
Infection Control Businessreportable segmentsegment profit2021-01-01 → 2021-12-31−¥4.9bn
Pharmaceuticals Businessreportable segmentcapex2021-01-01 → 2021-12-31¥656m
Pharmaceuticals Businessreportable segmentdepreciation2021-01-01 → 2021-12-31¥359m
Pharmaceuticals Businessreportable segmentrevenue2021-01-01 → 2021-12-31¥4.3bn
Pharmaceuticals Businessreportable segmentrevenue external2021-01-01 → 2021-12-31¥4.3bn
Pharmaceuticals Businessreportable segmentsegment assetsat 2021-12-31¥10.0bn
Pharmaceuticals Businessreportable segmentsegment profit2021-01-01 → 2021-12-31¥1.5bn
Total Of Reportable Segments And Otherssegment totalcapex2021-01-01 → 2021-12-31¥965m
Total Of Reportable Segments And Otherssegment totaldepreciation2021-01-01 → 2021-12-31¥831m
Total Of Reportable Segments And Otherssegment totalrevenue2021-01-01 → 2021-12-31¥11.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-01-01 → 2021-12-31¥11.3bn
Total Of Reportable Segments And Otherssegment totalsegment assetsat 2021-12-31¥14.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-01-01 → 2021-12-31−¥3.5bn
Infection Control Businessreportable segmentemployeesat 2022-12-3159 pure
Pharmaceuticals Businessreportable segmentemployeesat 2022-12-3191 pure
—segment totalemployeesat 2022-12-31150 pure

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,494
ItemContextValueUnit
Payout ratio (5-year summary)Prior1YearDuration_NonConsolidatedMember－
Payout ratio (5-year summary)CurrentYearDuration_NonConsolidatedMember－
Number of employeesPrior4YearInstant_NonConsolidatedMember207
Number of employeesPrior3YearInstant_NonConsolidatedMember211
Number of employeesPrior2YearInstant_NonConsolidatedMember237
Number of employeesPrior1YearInstant_NonConsolidatedMember226
Number of employeesCurrentYearInstant_NonConsolidatedMember175
Average number of temporary workersPrior4YearInstant_NonConsolidatedMember27
Average number of temporary workersPrior3YearInstant_NonConsolidatedMember40
Average number of temporary workersPrior2YearInstant_NonConsolidatedMember60
Average number of temporary workersPrior1YearInstant_NonConsolidatedMember23
Average number of temporary workersCurrentYearInstant_NonConsolidatedMember22
Total shareholder returnPrior4YearInstant_NonConsolidatedMember0.943
Total shareholder returnPrior3YearInstant_NonConsolidatedMember2.341
Total shareholder returnPrior2YearInstant_NonConsolidatedMember2.461
Total shareholder returnPrior1YearInstant_NonConsolidatedMember1.297
Total shareholder returnCurrentYearInstant_NonConsolidatedMember0.661
Total return on share price indexPrior4YearInstant_NonConsolidatedMember0.927
Total return on share price indexPrior3YearInstant_NonConsolidatedMember0.817
Total return on share price indexPrior2YearInstant_NonConsolidatedMember1.051
Total return on share price indexPrior1YearInstant_NonConsolidatedMember1.161
Total return on share price indexCurrentYearInstant_NonConsolidatedMember1.102
Number of employeesCurrentYearInstant_jpcrp030000-asr_E22560-000PharmaceuticalsBusinessReportableSegmentsMember109
Average number of temporary workersCurrentYearInstant_jpcrp030000-asr_E22560-000PharmaceuticalsBusinessReportableSegmentsMember11
Number of employeesCurrentYearInstant_jpcrp030000-asr_E22560-000InfectionControlBusinessReportableSegmentsMember76
Average number of temporary workersCurrentYearInstant_jpcrp030000-asr_E22560-000InfectionControlBusinessReportableSegmentsMember8
Number of employeesCurrentYearInstant_OtherReportableSegmentsMember－
Average number of temporary workersCurrentYearInstant_OtherReportableSegmentsMember－
Number of employeesCurrentYearInstant_ReportableSegmentsMember185
Average number of temporary workersCurrentYearInstant_ReportableSegmentsMember19
Number of employeesCurrentYearInstant_CorporateSharedMember25
Average number of temporary workersCurrentYearInstant_CorporateSharedMember3
Number of employeesCurrentYearInstant210
Average number of temporary workersCurrentYearInstant22
Number of employeesCurrentYearInstant_NonConsolidatedMember175
Average number of temporary workersCurrentYearInstant_NonConsolidatedMember22
Average age years information about reporting company information about employeesCurrentYearInstant_NonConsolidatedMember41.6
Average length of service years information about reporting company information about employeesCurrentYearInstant_NonConsolidatedMember10.8
Average annual salary information about reporting company information about employeesCurrentYearInstant_NonConsolidatedMember6245308JPY
Number of employeesCurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E22560-000PharmaceuticalsBusinessReportableSegmentsMember91
Average number of temporary workersCurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E22560-000PharmaceuticalsBusinessReportableSegmentsMember11
Number of employeesCurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E22560-000InfectionControlBusinessReportableSegmentsMember59
Average number of temporary workersCurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E22560-000InfectionControlBusinessReportableSegmentsMember8
Number of employeesCurrentYearInstant_NonConsolidatedMember_OtherReportableSegmentsMember－
Average number of temporary workersCurrentYearInstant_NonConsolidatedMember_OtherReportableSegmentsMember－
Number of employeesCurrentYearInstant_NonConsolidatedMember_ReportableSegmentsMember150
Average number of temporary workersCurrentYearInstant_NonConsolidatedMember_ReportableSegmentsMember19
Number of employeesCurrentYearInstant_NonConsolidatedMember_CorporateSharedMember25
Average number of temporary workersCurrentYearInstant_NonConsolidatedMember_CorporateSharedMember3
Number of employeesCurrentYearInstant_NonConsolidatedMember175

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 24 of 24 passed
balance sheet identityconsolidated 2021-12-31pass
balance sheet identityconsolidated 2022-12-31pass rounding
balance sheet identitynon_consolidated 2021-12-31pass
balance sheet identitynon_consolidated 2022-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2020-12-31pass
statement vs summary · net assetsconsolidated 2021-12-31pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net assetsnon_consolidated 2020-12-31pass
statement vs summary · net assetsnon_consolidated 2021-12-31pass
statement vs summary · net assetsnon_consolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-01-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2021-01-01/2021-12-31pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-01-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-01-01/2022-12-31pass
statement vs summary · revenuenon_consolidated 2021-01-01/2021-12-31pass
statement vs summary · revenuenon_consolidated 2022-01-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2021-12-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsnon_consolidated 2021-12-31pass
statement vs summary · total assetsnon_consolidated 2022-12-31pass